Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7189260 | 0.99 | PLA2G4B (0.45) | PLA2G4BPTPN11SMPD1THRATHRB | |
| SCHEMBL7188708 | 0.98 | PPARG (0.43) | PLA2G4BPTPN11SMPD1PTGESALOX5 | |
| Lithium SCHEMBL7188712 | 0.95 | PPARG (0.43) | PLA2G4BPTPN11SMPD1PTGESALOX5 | |
| SCHEMBL7179721 | 0.93 | KMT2A (0.43) | PTGESALOX5PPARGPPARA | |
| SCHEMBL7177730 | 0.92 | PLA2G4B (0.39) | PLA2G4BPTPN11SMPD1PTGESALOX5 | |
| SCHEMBL7187880 | 0.92 | PLA2G4B (0.41) | PLA2G4BPTPN11SMPD1THRATHRB | |
| SCHEMBL7177461 | 0.91 | ITGB1 (0.48) | PLA2G4BPTPN11THRATHRB | |
| SCHEMBL7177011 | 0.91 | THRA (0.45) | PLA2G4BPTPN11SMPD1THRATHRB | |
| Lithium SCHEMBL7179726 | 0.91 | KMT2A (0.43) | PTGESALOX5PPARGPPARA | |
| Lithium SCHEMBL7177734 | 0.90 | PLA2G4B (0.39) | PLA2G4BPTPN11SMPD1PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | PLA2G4B 2769/4885PTPN11 82/4885SMPD1 2336/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | PLA2G4B 2441/4885PTPN11 96/4885SMPD1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.